Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04938609 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC)
A Phase 2 study of Head and Neck Cancer and Head and Neck Squamous Cell Carcinoma, sponsored by Providence Health & Services.
- Active
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 3
- Study locations
NCT04938609: Active Phase 2 study of Head and Neck Cancer and Head and Neck Squamous Cell Carcinoma, sponsored by Providence Health & Services.
NCT04938609 is a Phase 2 study of Head and Neck Cancer and Head and Neck Squamous Cell Carcinoma that is active but no longer recruiting, run by Providence Health & Services. The registered enrollment target is 28 participants, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (89% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04938609, a Phase 2 study of Head and Neck Cancer and Head and Neck Squamous Cell Carcinoma, is active but no longer recruiting, sponsored by Providence Health & Services.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy of neoadjuvant immunoradiotherapy (NIRT) prior to surgery for the treatment of stage III and IVA HPV- HNSCC.
Primary Outcome
Prior to surgery neoadjuvant immunoradiotherapy (NIRT) with stereotactic body radiation therapy (SBRT) + pembrolizumab in stage III-IVA HPV-negative HNSCC patients.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- PROCEDURE Surgical Resection
- RADIATION Stereotactic Body Radiation Therapy (5 days)
Study Locations (3)
Oregon
- Portland Providence Medical Center - Portland
- Providence St. Vincent Medical Center - Portland
California
- University of San Diego - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2022-01-11 |
| Est. Completion | 2031-01-11 |
| Phase | Phase 2 |
What the registry record for NCT04938609 still lists
NCT04938609 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (89% lower).
The record links to 2 conditions, with Head and Neck Cancer appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT04938609 reports a single indexed study location in Oregon, California.
Frequently Asked Questions
What is clinical trial NCT04938609 about?
NCT04938609 is a clinical study titled "Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC)". The purpose of this study is to evaluate the efficacy of neoadjuvant immunoradiotherapy (NIRT) prior to surgery for the treatment of stage III and IVA HPV- HNSCC.
What is the current status of trial NCT04938609?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2022-01-11. Estimated completion is 2031-01-11.
What conditions does trial NCT04938609 study?
This clinical trial studies the following conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma.
What interventions are being tested in trial NCT04938609?
The interventions under investigation include: Pembrolizumab (DRUG), Surgical Resection (PROCEDURE), Stereotactic Body Radiation Therapy (5 days) (RADIATION).
Who is sponsoring clinical trial NCT04938609?
This trial is sponsored by Providence Health & Services, which has 69 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04938609 being conducted?
This trial has 3 study locations across California, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04938609's enrollment target sits among peer trials
28 188th of 250 higher than 60 of 250 other Head and Neck Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Head and Neck Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase II Panitumumab-IRDye800 in Head & Neck Cancer
RECRUITING · Phase 2
-
ATATcH Alternating Treatment Plans for Advanced Cancer
RECRUITING · Phase 2
-
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
RECRUITING · Phase 2
-
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
RECRUITING · Phase 2
-
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
RECRUITING · Phase 2
-
A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI